Skip to main content

Table 2 Dose-volume and follow-up parameters for robotic stereotactic ablative body radiotherapy

From: Robotic stereotactic ablative radiotherapy for renal cell carcinoma in patients with impaired renal function

Case GTV (cm3) PTV (cm3) Margin (mm) Dose (Gy) PTV coverage (%) nCI Follow-up (month) Local control
#1 8.2 17.9 4 1 × 24 97.8 1.07 54 SD
#2 20.4 31.0 3 1 × 25 97.8 1.06 23 PR
#3 13.5
17.0
13.5
17.0
0
0
1 × 24
1 × 24
96.8
98.5
1.13
1.13
47 CR
PR
#4 14.3 24.6 3 1 × 25 99.9 1.06 33 SD
#5 108.4 190.3 5 3 × 12 92.0 1.23 25 SD
#6 13.2 22.7 3 1 × 25 99.5 1.13 15 SD
#7 9.2 17.4 3 3 × 12 98.3 1.14 32 SD
#8 45.5 88.4 5 3 × 12 86.0 1.40 30 PD
#9 44.2 66.2 3 3 × 12 98.7 1.21 23 PR
#10 1.3
9.0
2.3
3.8
21.4
5.6
3
4
3
1 × 25
3 × 12
1 × 25
99.7
82.0
98.4
1.09
1.50
1.20
16 CR
PR
CR
  1. GTV Gross tumor volume, PTV planning target volume, nCI new conformity index, SD stable disease, PR partial remission, CR complete remission, PD progressive disease